Literature DB >> 33083356

Long-lasting Thrombocytopenia after Transient Pancytopenia Induced by Short-Term Concomitant Radiotherapy and Temozolomide.

Aleksandar Stepanović1, Marina Nikitović1,2, Andrija Bogdanović2,3, Danica Grujičić2,4.   

Abstract

We describe long-lasting and incompletely resolved thrombocytopenia after transient profound pancytopenia in a 62-year-old female patient with glioblastoma after short-term radiotherapy with temozolomide. Pancytopenia was present for more than 4 weeks and thrombocytopenia for more than 6 months, without platelet recovery to normal levels. LEARNING POINTS: Some patients may experience severe haematological manifestations after even short-term radiotherapy with temozolomide.In everyday practice, clinical models precisely predicting the haematological toxicity of concomitant treatment with temozolomide and radiotherapy is necessary, especially in countries where genetic tests are not available.Incomplete recovery of the cells of a particular bloodline over a long period may necessitate permanent discontinuation of chemotherapy or radiotherapy. © EFIM 2020.

Entities:  

Keywords:  Glioblastoma; pancytopenia; temozolomide; thrombocytopenia

Year:  2020        PMID: 33083356      PMCID: PMC7546554          DOI: 10.12890/2020_001785

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  8 in total

Review 1.  Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.

Authors:  Marc C Chamberlain
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

2.  Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.

Authors:  Alexander Tinchon; Stefan Oberndorfer; Christine Marosi; Andreas Gleiss; Angelika Geroldinger; Cornelia Sax; Camillo Sherif; Walter Moser; Wolfgang Grisold
Journal:  J Neurol       Date:  2014-10-31       Impact factor: 4.849

3.  Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.

Authors:  Terri S Armstrong; Yumei Cao; Michael E Scheurer; Elizabeth Vera-Bolaños; Rochelle Manning; Mehmet F Okcu; Melissa Bondy; Renke Zhou; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

Review 4.  MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.

Authors:  Meric A Altinoz; Ilhan Elmaci; Fatih Han Bolukbasi; Cumhur Gokhan Ekmekci; Guven Yenmis; Ramazan Sari; Aydin Sav
Journal:  J Chemother       Date:  2017-04-23       Impact factor: 1.714

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  Persistent bone marrow depression following short-term treatment with temozolomide.

Authors:  Kathrine Vandraas; Geir Erland Tjønnfjord; Tom Børge Johannesen; Petter Brandal
Journal:  BMJ Case Rep       Date:  2016-04-29

8.  Metronidazole caused profound drug-induced immune thrombocytopenia.

Authors:  Jeffrey Lew; Jeffrey Berenberg
Journal:  Clin Case Rep       Date:  2017-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.